Summary
The widespread use of neurosurgical devices for intraventricular drug delivery has led to an escalation in the number of CSF pharmacokinetic studies. When experimental data for ventricular CSF concentration vs. time are normalized for dose and plotted for drugs with a wide range of physical properties, there is a remarkably narrow range. Simulations from a distributed model for the central nervous system suggest that the narrow range of observed CSF half-times following bolus administration is a consequence of physiologic limits upon rate of drug removal from CSF. Whereas bulk flow of CSF establishes a minimum rate of drug washout, diffusion through brain tissue and subsequent removal by capillaries establishes a maximum rate of drug egress which is only seven times the minimum rate. Predictions of CSF concentration vs. time can be made based upon the capillary exchange rate for a particular drug, which could be estimated or calculated from CSF concentration measurements following systemic administration. Simulations are also presented of steady-state CSF concentrations during continuous ventricular infusions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Poplack DG: Acute lymphoblastic leukemia and less frequently occuring leukemias in the young. In: AS Levine (ed): Cancer in the Young. Masson Pub., New York, 1982, pp 405–460.
Wasserstrom WR, Glass JP, Posner JB: Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49:759–772, 1982.
Aisner J, Aisner SC, Ostrow S, Govindan S, Mummert K, Wiernik P: Meningeal carcinomatosis from small cell carcinoma of the lung: consequence of improved survival. Acta Cytologica 23:292–296, 1979.
Shapiro WR, Young DF, Mehta BM: Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 293:161–166, 1975.
Kaiser AB, McGhee ZA: Aminoglycoside therapy of gram-negative bacillary meningitis. N Engl J Med 293:1215–1220, 1975.
6.Zimm S, Collins JM, Riccardi R, O'Neill D, Narang PK, Chabner B, Poplack DG: Variable biovailability of oral mercaptopurine: is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J M 308: 1005–1009, 1983.
Wood JH, Poplack DG, Flor WJ, Gunby EN, Ommaya AK: Chronic ventricular cerebrospinal fluid sampling, drug injections, and pressure monitoring using subcutaneous reservoirs in monkeys. Neurosurg 1:132–135, 1977.
Poplack DG: Bleyer WA, Wood JH, Kostolich M, Savitch JL, Ommaya AK: A primate model for study of methotrexate pharmacokinetics in the central nervous system. Cancer Res 37:1982–1985, 1977.
Gangji D, Poplack DG, Schwade J, Wood JH, Strong J: Misonidazole blood and cerebrospinal fluid kinetics in monkeys following intravenous and intrathecal administration. Eur J Cancer 17:29–34, 1981.
Gormley PE, Gangji D, Wood JH, Poplack DG: Pharmacokinetic study of cerebrospinal fluid penetration of cis-diamminedichloroplatinum (II). Cancer Chemother Pharmacol 5:257–260, 1981.
Zimm S, Collins JM, Curt G, O'Neill D, Poplack D: The cerebrospinal fluid (CSF) pharmacokinetics of intrathecal diaziquone (AZQ) (Abstract). Proc Am Assoc Cancer Res 24:291, 1983.
Narang PK, Chatterji DC, O'Neill D, Poplack DG: Pharmacokinetics of 6-mercaptopurine in the monkey. II. Disposition from CSF and plasma following intrathecal bolus. Proceedings of the 33rd National Meeting of the American Pharmacological Association Academy, San Diego, ca. 1982.
Riccardi R, Kramer MJ, Trown PW, O'Neill D, Levine AS, Poplack DG: Serum and cerebrospinal fluid (CSF) pharmacokinetics of recombinant leucocyte A interferon (ILFrA) in monkeys (Abs.). Proc Am Assoc Cancer Res 23:203, 1982.
Collins JM, Dedrick RL: A distributed model for drug delivery to the brain: relationship between CSF and tissue concentrations. Am J Physiol 245: R303-R310, 1983.
Mapleson WW: An electric analogue for uptake and exchange of inert gases and other agents. J Appl Physiol 18:197–204, 1963.
Blasberg R, Patlak CS, Shapiro WR: Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration. Cancer Treat Rep 61:633–641, 1977.
Blasberg R, Patlak CS, Fenstermacher JD: Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther 195:73–83, 1975.
Patlak CS, Fenstermacher JD: Measurements of dog bloodbrain transfer constants by ventriculocisternal perfusion. Am J Physiol 229:877–884, 1975.
Fenstermacher JD, Blasberg RG, Patlak CS: Methods for quantifying the transport of drugs across brain barrier systems. Pharmacol Ther 14:217–248, 1981.
Dedrick RL, Zaharko DS, Bender RA, Bleyer WA, Lutz RJ: Pharmacokinetic considerations on resistance to anticancer drugs. Cancer Chemother Rep 59:795–804, 1975.
Bleyer WA, Poplack DG: Clinical studies on the central nervous system pharmacology of methotrexate. In: HM Pinedo (ed): Clinical Pharmacology of Anti-Neoplastic Drugs. Elsevier/North Holland, Amsterdam, 1978, pp 115–131.
Dakhil S, Ensminger W, Kindt G, Niederhuber J, Chandler W, Greenberg H, Wheeler R: Implanted system for intraventricular drug infusion in central nervous system tumors. Cancer Treat Rep 65:401–411, 1981.
Carnahan B, Luther HA, Wilkes JO: Applied Numerical Methods. Wiley, New York, 1969, pp 429–530.
Crank J: The Mathematics of Diffusion. Oxford University Press, Oxford, 1956, pp 30–31.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Collins, J.M. Pharmacokinetics of intraventricular administration. J Neuro-Oncol 1, 283–291 (1983). https://doi.org/10.1007/BF00165710
Issue Date:
DOI: https://doi.org/10.1007/BF00165710